SMMT - Summit Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

Currency in GBP. All numbers in thousands
Breakdown
ttm
1/30/2019
1/30/2018
1/30/2017
Total Revenue
1,004
43,012
25,419
2,304
Cost of Revenue
-
19
69
-
Gross Profit
-
42,993
25,350
-
Operating Expenses
Research Development
34,247
39,174
28,970
18,952
Selling General and Administrative
2,735
12,342
11,999
8,277
Total Operating Expenses
25,226
36,360
38,244
27,157
Operating Income or Loss
-24,241
6,652
-12,825
-24,853
Interest Expense
-
424
1,164
862
Total Other Income/Expenses Net
-
-
-
0
Income Before Tax
-24,741
5,031
-10,893
-25,707
Income Tax Expense
-3,397
-2,496
-3,762
-4,336
Income from Continuing Operations
-21,344
7,527
-7,131
-21,371
Net Income
-21,344
7,527
-7,131
-21,371
Net Income available to common shareholders
-21,344
7,527
-7,131
-21,371
Reported EPS
Basic
-
0.45
-0.55
-1.75
Diluted
-
0.45
-0.55
-1.75
Weighted average shares outstanding
Basic
-
17,140
13,087
12,310
Diluted
-
17,140
13,087
12,310
EBITDA
-
6,593
-9,483
-24,787